Navigation Links
One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
Date:10/27/2008

ients experienced SAEs and no tuberculosis or opportunistic infections were reported. Between weeks 24 and 52, one colon and one small cell lung cancer were reported. The small cell lung cancer patient died; another patient died in a climbing accident. Through one year, golimumab had a similar safety profile to the first 6 months.

Anti-TNF therapies have been associated with serious and sometimes fatal risks including the risk of tuberculosis and other serious infections, malignancies, heart failure, central nervous system disorders, reactivation of hepatitis B and other serious events.

About Psoriatic Arthritis

Psoriatic arthritis is a chronic inflammatory arthropathy manifesting with joint pain and swelling that can lead to joint destruction and debilitation. It is frequently associated with inflamed, scaly, red patches of skin psoriasis and psoriasis nail involvement. Symptoms may include stiffness and tenderness of the joints and surrounding tissue and reduced range of motion. Joints of the hands, wrists, knees, ankles, feet, lower back and neck are commonly affected. Psoriasis affects an estimated two to three percent of the world's population, and approximately one out of three patients affected by psoriasis may develop psoriatic arthritis. Both men and women are equally affected by psoriatic arthritis, most commonly between the ages 30 and 50, in the peak of their productive years.

About Golimumab

Golimumab, the next-generation human anti-TNF-alpha monoclonal antibody from Centocor Inc. and Schering-Plough Corporation, is currently in the most comprehensive Phase 3 development program to date for an anti-TNF-alpha biologic therapy. With ongoing studies for the treatment of rheumatoid arthritis (RA), psoriatic arthritis and ankylosing spondylitis, golimumab is being studied as an every four-week subcutaneous injection and an intravenous (IV) infusion therapy. Golimumab targets and neutralizes both the soluble and membrane-bou
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
2. Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
3. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
4. In-Room Computers and Wall-Mounted Proximity Systems Computer WorkStations Deliver Increased Efficiency; Improved Patient Care
5. Finesse Solutions Launches Improved E-Store for Sensors and Transmitters
6. Kelly Osbourne and International Health Groups Call for Improved Education on Choices and Usage of Contraception
7. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
8. Improved culture system for hepatitis C virus infection
9. Pharmacy Students Taught Improved Medication Adherence and Holistic Health Services Through Program Incorporating InforMedixs Med-eXpert(TM) System
10. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
11. China Kangtai Cactus Biotech Announces Improved Milk Production in Cows From Companys Cactus Cattle Feed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 1, 2015  Northwest Biotherapeutics (NASDAQ: NWBO ) ... immune therapies for solid tumor cancers, announced today that ... tranche of a $40 million investment from Woodford investment ... invested $25 million in NW Bio on November 19, ... agreement with the Company for a further $40 million ...
(Date:5/1/2015)... 1, 2015 Pfenex Inc. (NYSE MKT: ... development of biosimilar therapeutics including high value and ... first quarter 2015 financial results will be released ... of market. At 8:30 am Eastern Time, Pfenex management ... financial results and provide a business update. A press ...
(Date:5/1/2015)... 1, 2015 Investor-Edge has ... Ltd (NASDAQ: GENE ), Agilent Technologies Inc. ... (NYSE: TMO ), Sequenom Inc. (NASDAQ: ... ). Free research report on Genetic Technologies can ... April 30, 2015, the NASDAQ Composite ended at ...
(Date:5/1/2015)... SPRING, Md. and RESEARCH TRIANGLE PARK, ... (NASDAQ: UTHR ) announced today that Roger Jeffs ... will provide an overview and update on the company,s business ... Conference in Boston, Massachusetts . ... at 3:30 PM Eastern Time, and can be accessed via ...
Breaking Biology Technology:NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 2NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 3Pfenex To Report First Quarter 2015 Results and Provide Business Update on Thursday, May 14, 2015 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5
... Security Research Consortium held an organizational meeting last week ... bring classified research to Wisconsin institutions. , ,Tom Hefty, ... president of the board of directors. He is now ... , Paul Peercy , dean of the UW-Madison ...
... There are few better ways to promote your business than ... web site. , ,Good content attracts good traffic. , ,On ... on the Internet, according to the PEW Internet and ... activities include getting news and finding information via search engines. ...
... reflection, and this one is no different. These last 12 months ... doubt look back on 2005 and pronounce it the year the ... of things, the previous four years were a standing eight count, ... like hell and a lot was lost on bad bets, but ...
Cached Biology Technology:The write stuff: marketing with articles 2The write stuff: marketing with articles 3The write stuff: marketing with articles 42005: the year of the comeback 22005: the year of the comeback 3
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/2/2015)... 2015 According to preliminary estimates ... somewhat higher than 125 MSEK. This exceeds the guidance ... that revenues for Q1 2015 would be in line ... Q4 2014. The operating result for the first quarter ... interim report will as previously communicated be published on ...
(Date:4/1/2015)... , Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... smart wallets is underway to early access pre-order customers. ... includes usage at retail outlets including Walmart, Target, AT&T, ... report Wocket was accepted at all outlets and very ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4
... 2010 ... ... ... Results are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
... mice that can "smell" light, providing a potent new tool ... olfaction. The work, described this week in the journal ... of smell and of complex perception systems that do not ... makes intuitive sense to use odors to study smell," says ...
... YORK, Sept. 21 Global Rainmakers, Inc. (GRI), ... and advanced R&D laboratory, today announced the appointment of ... be responsible for overseeing firm operations as it ... Demitrieus, 62, comes to GRI with ...
Cached Biology News:Almac has Successful MHRA Inspection at its Clinical Services UK Site 2Almac has Successful MHRA Inspection at its Clinical Services UK Site 3Almac has Successful MHRA Inspection at its Clinical Services UK Site 4Almac has Successful MHRA Inspection at its Clinical Services UK Site 5Almac has Successful MHRA Inspection at its Clinical Services UK Site 6Almac has Successful MHRA Inspection at its Clinical Services UK Site 7Almac has Successful MHRA Inspection at its Clinical Services UK Site 8Mice that 'smell' light could help us better understand olfaction 2Global Rainmakers Appoints James M. Demitrieus as Chief Operating Officer 2Global Rainmakers Appoints James M. Demitrieus as Chief Operating Officer 3
Homo sapiens HCLS1 associated protein X-1 Antigen: Recombinant Protein...
See product name for description....
Amino Acid Analysis is performed using ion-exchange separation of the amino acids from acid hydrolysates, followed by ninhydrin detection. Typical quantities required are 0.1 to 0.5 mg, depending on...
...
Biology Products: